Checkpoint inhibitor induced hepatitis and the relation with liver metastasis and outcome in advanced melanoma patients
Authors:
Open Access
- 25 February 2021
- journal article
- research article
- Published by Springer Nature in Hepatology International
- Vol. 15 (2) , 510-519
Abstract
Background: Checkpoint inhibitor-induced hepatitis is an immune-related adverse event of programmed cell death protein 1 (PD-1) inhibition, cytotoxic T-lymphocyte associated 4 (CTLA-4) inhibition or the combination of both. Aim of this study was to assess whether checkpoint inhibitor-induced hepatitis is related to liver metastasis and outcome in a real-world nationwide cohort. Methods: Data from the prospective nationwide Dutch Melanoma Treatment Registry (DMTR) was used to analyze incidence, risk factors of checkpoint inhibitor-induced grade 3–4 hepatitis and outcome. Results: 2561 advanced cutaneous melanoma patients received 3111 treatments with checkpoint inhibitors between May 2012 and January 2019. Severe hepatitis occurred in 30/1620 (1.8%) patients treated with PD-1 inhibitors, in 29/1105 (2.6%) patients treated with ipilimumab and in 80/386 (20.7%) patients treated with combination therapy. Patients with hepatitis had a similar prevalence of liver metastasis compared to patients without hepatitis (32% vs. 27%; p = 0.58 for PD-1 inhibitors; 42% vs. 29%; p = 0.16 for ipilimumab; 38% vs. 43%; p = 0.50 for combination therapy). There was no difference in median progression free and overall survival between patients with and without hepatitis (6.0 months vs. 5.4 months progression-free survival; p = 0.61; 17.0 vs. 16.2 months overall survival; p = 0.44). Conclusion: Incidence of hepatitis in a real-world cohort is 1.8% for PD-1 inhibitor, 2.6% for ipilimumab and 20.7% for combination therapy. Checkpoint inhibitor-induced hepatitis had no relation with liver metastasis and had no negative effect on the outcome.Keywords
Funding Information
- Nederlands Instituut voor Onderzoek van de Gezondheidszorg (836002002)
This publication has 37 references indexed in Scilit:
- Evaluation of clinicopathological factors in PD-1 response: derivation and validation of a prediction scale for response to PD-1 monotherapyBritish Journal of Cancer, 2017
- Dutch Melanoma Treatment Registry: Quality assurance in the care of patients with metastatic melanoma in the NetherlandsEuropean Journal of Cancer, 2017
- Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and NeckNew England Journal of Medicine, 2016
- Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptorEuropean Journal of Cancer, 2016
- Combined Nivolumab and Ipilimumab or Monotherapy in Untreated MelanomaNew England Journal of Medicine, 2015
- Vitiligo-Like Depigmentation in Patients With Stage III-IV Melanoma Receiving Immunotherapy and Its Association With Survival: A Systematic Review and Meta-AnalysisJournal of Clinical Oncology, 2015
- Lactate dehydrogenase as a selection criterion for ipilimumab treatment in metastatic melanomaCancer Immunology, Immunotherapy, 2014
- Ipilimumab associated hepatitis: imaging and clinicopathologic findingsInvestigational New Drugs, 2013
- Management of Immune-Related Adverse Events and Kinetics of Response With IpilimumabJournal of Clinical Oncology, 2012
- The Emerging Toxicity Profiles of Anti–CTLA-4 Antibodies Across Clinical IndicationsSeminars in Oncology, 2010